Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action

J Infect Dis. 1991 May;163(5):1114-20. doi: 10.1093/infdis/163.5.1114.


Current therapy of cryptococcosis is unsatisfactory, particularly in patients with AIDS. Experimental cryptococcosis models in DBA/2 mice were used to determine whether the murine monoclonal anticryptococcal antibody (designated E1) might potentiate the chemotherapeutic effect of amphotericin B (AmB). According to the inoculum size, these mice died spontaneously from acute pneumonia (high inoculum) or from brain swelling (lower inoculum). AmB and E1 together significantly improved the survival of mice in both models compared with AmB alone. The mechanisms by which E1 might potentiate AmB activity were investigated in vitro. When cryptococci were preincubated with AmB or another polyene antibiotic, nystatin, there was an augmented binding of E1. AmB enhanced phagocytosis by unstimulated peritoneal macrophages in the presence of E1 or normal rabbit immunoglobulins. Normal and immune IgG deserve further study to determine under what circumstances the chemotherapeutic effect of AmB can be enhanced.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / pharmacology
  • Amphotericin B / therapeutic use*
  • Animals
  • Antibodies, Fungal / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Cells, Cultured
  • Combined Modality Therapy
  • Cryptococcosis / therapy*
  • Cryptococcus neoformans / drug effects
  • Cryptococcus neoformans / immunology*
  • Flow Cytometry
  • Immunization, Passive
  • Macrophages / immunology
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred DBA
  • Phagocytosis


  • Antibodies, Fungal
  • Antibodies, Monoclonal
  • Amphotericin B